Marcel Hop

I joined Genentech in 2007 as director of the small molecule Drug Metabolism & Pharmacokinetics department. The mission of the DMPK department is to enable the discovery, selection, development, and commercialization of medicines for significant unmet medical needs by elucidating the absorption, distribution, metabolism, elimination and pharmacokinetic/pharmacodynamic properties of small molecule drug candidates and antibody-drug conjugates. We accomplish this through application of state-of-the-art technologies, drug metabolism and disposition expertise, bioanalysis, innovative thinking, effective collaboration and teamwork.

Drug discovery and development continues to be extremely challenging and success is only achievable by integrating the contributions from excellent scientists here at Genentech. Having everyone on one campus is ideal, because you can simply walk over and discuss the latest data and next steps.

Genentech's strength lies in its deep knowledge of the biology as it relates to oncology, immunology, CNS disorders and bacterial infections. ADME in drug discovery and development is a rapidly evolving field and we have great opportunities to apply the latest science to identify molecules that are ideal candidates for clinical testing. It is critically important to emphasize continuous learning – talk to and listen to in house colleagues, read the literature diligently and attend relevant conferences. Keep your skills sharp, process everything and apply the best approaches to your projects.